%0 Journal Article
%T Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease
%A Adam J. Schwarz
%A Bradford C. Dickerson
%A David Scott
%A Eric R. Siemers
%A Joonmi Oh
%A Joyce Suhy
%A Karen L. Sundell
%A Luc Bracoud
%A Michael G. Case
%A Michael J. Pontecorvo
%A Ralf K. Jaeger
%J Archive of "Alzheimer's & Dementia : Translational Research & Clinical Interventions".
%D 2019
%R 10.1016/j.trci.2019.05.007
%X Solanezumab is a humanized monoclonal antibody that preferentially binds to soluble amyloid ¦Â and promotes its clearance from the brain in preclinical studies. The objective of this study was to assess the effect of solanezumab in slowing global and anatomically localized brain atrophy as measured by volumetric magnetic resonance imaging (MRI)
%K Solanezumab
%K Amyloid
%K Volumetric magnetic resonance imaging
%K MRI
%K Alzheimer disease
%K Atrophy
%K Cognition
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675941/